COPD

Mobile Apps for Chronic Diseases Management

Jun 06, 2025

Assessing the Growing Role & the Demand of Chronic Disease Management Apps

evolving-landscape-of-copd-treatments

Dec 20, 2024

The Evolving Landscape of COPD Treatments: New Hope for Patients

dupixent-for-copd

Oct 07, 2024

DUPIXENT Receives First-Ever Biologic Approval for COPD: Adds Another Jewel in its Crown

Pharma-news-for-bms-intrabio-pfizer

Oct 01, 2024

IntraBio’s AQNEURSA Niemann-Pick Disease Approval; FDA Approves Novel Schizophrenia Drug After 35 Years; Selpercatinib Gets FDA Nod for RET-Mutated MTC; DUPIXENT Receives First-Ever COPD Approval; Pfizer Withdraws OXBRYTA for Sickle Cell Disease from Global Market

Pharma-news-for-biogen-travere-GSK

Sep 10, 2024

Biogen’s SPINRAZA Phase II/III Trial Results; Travere’s FILSPARI FDA Approval; GSK’s NUCALA Succeeds in COPD Trial; Summit’s NSCLC Win Over KEYTRUDA Raises Caution; FDA Lifts Hold on RZ358 for Congenital Hyperinsulinism

pharma-news-for-eli-lilly-ideaya-roche-sanofi

Jul 09, 2024

Lilly’s Morphic Acquisition; IDEAYA’s IDE397 Positive Phase II Trial Result; XPOVIO (selinexor) Approval in China; Roche to Reintroduce Susvimo in the US; Dupixent EU Approval

pharma-news-for-eisai-merck-verona-astrazeneca

Jul 02, 2024

Eisai Announces Solo Development of Farletuzumab Ecteribulin (FZEC); Johnson & Johnson’s Nipocalimab Phase III Trial; Merck’s WINREVAIR  EU CHMP Recommendation;  Verona Pharma’s  Ohtuvayre FDA Approval; AstraZeneca’s Lynparza and Imfinzi EU Approval

Airway Management Devices Market Insights

Jan 24, 2024

Airway Management Devices: Charting the Evolving Market Trends and Key Innovations

Opioid-Induced Respiratory Depression Market Outlook

Dec 22, 2023

Opioid-Induced Respiratory Depression: Unveiling the Silent Threat

Pharma News for Sanofi, Sosei, AstraZeneca, Arcturus

Nov 28, 2023

Dupixent Significantly Reduced COPD Exacerbations; Sosei Heptares to Regain Ownership of GSK4381406; AstraZeneca Gains Rights to Usynova’s KRAS Inhibitor; FDA Approvs OGSIVEO for Desmoid Tumors; Orphan Drug Designation for ARCT-032 for the Cystic Fibrosis; FDA Fast Track Designation for ADP101 for Food Allergies

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper